ReviewHealthcare (Basel, Switzerland)2023
Review in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Clinical Characteristics, Management and Outcomes of Nonintensive Care Unit Candidemia: Subanalysis of the ECMMOpen forum infectious diseases · 2026Trial
- The Immunomodulatory Effects of Mannan on the Fungicidal Activity of Macrophages AgainstMicroorganisms · 2026Article
- Study Clinical Characteristics and Outcomes ofJournal of clinical medicine · 2026Article
- Fluconazole Disk Diffusion on CHROMagar Candida Plus for Differentiation BetweenJournal of fungi (Basel, Switzerland) · 2026Article
- Isolation and Genomic Profiling of Multi-Drug-Resistant pathogen Candidozyma auris, Including the New Clade VI, Through Wastewater Surveillance in Abu Dhabi, United Arab Emirates.Communications medicine · 2026Article
- Article
- National Surveillance of Candidemia in the Czech Republic: Preliminary Results from the 2023 Multicentre Study.Mycopathologia · 2026Article
- Prospective surveillance of Candida auris and assessment of diagnostic approaches in a Belgian hospital.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Candidozyma auris in The Netherlands: No Evidence of Nosocomial Transmission Supported by Effective Infection Control Policies.Mycopathologia · 2026Article
- Essential oils as nature-engineered antifungals: a comprehensive review of pharmacological mechanisms, drug synergism, and advanced formulation strategies.Frontiers in pharmacology · 2026Review
- Active and Passive Immunization of Pan-Fungal Vaccine NXT-2 Reduces Morbidity and Mortality in an Immunosuppressed Murine Model ofVaccines · 2025Article
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- Fungal Biofilm: An Overview of the Latest Nano-Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- EnhancingMicrobiology spectrum · 2025Article
- Article
- Current Overview of Environmental Disinfection and Decolonization ofTropical medicine and infectious disease · 2025Review
- Distribution and prevalence of fungemia: a five-year retrospective multicentric survey in Venetian region, Italy.JAC-antimicrobial resistance · 2025Article
- Article
- Review
- Current Updates on Molecular Diagnostic Assays Used for Detection ofDiagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.